Breast cancer recurrence and metastatic spread explained - Video
|
Overview
Researchers from the University of Cincinnati and Cincinnati Children's Hospital Medical Center are studying the biology of breast cancer recurrence. The team led by UC's Susan Waltz and Susanne Wells published recent findings on biomarkers that help predict outcomes and could be targeted for new treatments in the journal PLOS ONE.
The research team found that the Ron and DEK genes can regulate certain metabolites, substances made or used when the body breaks down food, drugs or chemicals in the process of metabolism, to help cancer cells grow and spread.
By studying the enzymes involved, the team identified a metabolic signature that can help better predict outcomes for patients. In addition to being a helpful biomarker, the metabolic signature itself could be a potential target for new therapies.
For example, if a high level of a certain enzyme is predictive of better outcomes, nutritional supplements or other treatments can help promote that enzyme's activity. Alternatively, if high levels of a certain metabolite predict worse outcomes, treatments can reduce that metabolite by blocking the function of relevant enzymes in that pathway.
Ref:
Susan Waltz and Susanne Wells et al, NMR-based metabolomic analysis identifies RON-DEK-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival, PLoS ONE
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed
Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751